NeuroOne Medical (NMTC) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$9.5M

Revenue (quarter)

$2.0M

Revenue growth (year over year)

+16.34%

Gross profit (trailing twelve months)

$5.3M

Gross margin

55.65%

Net income (trailing twelve months)

−$7.4M

Net income (quarter)

−$2.0M

Net income growth (year over year)

−33.68%

Net margin

−78.63%

Return on equity

−124.66%

EPS (trailing twelve months)

−$0.90

Book value per share

$0.43

P/E (trailing twelve months)

—

Price to book

2.54

Debt to assets

39.10%

Payout ratio

—

Dividend yield

—

Company profile

NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.

• Is NeuroOne Medical (NMTC) profitable?

  No. NeuroOne Medical reported a net loss of $7.4M over the trailing twelve months.

• How much revenue does NeuroOne Medical (NMTC) make?

  NeuroOne Medical generated $9.5M in revenue over the trailing twelve months, up 16.34% year over year.

• How do I buy stock in NeuroOne Medical (NMTC)?

  NMTC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.